102 related articles for article (PubMed ID: 11469688)
1. Expression of a glypican-related 62-kDa antigen is decreased in hepatocellular carcinoma in correspondence to the grade of tumor differentiation.
Lage H; Kellner U; Tannapfel A; Dietel M
Virchows Arch; 2001 Jun; 438(6):567-73. PubMed ID: 11469688
[TBL] [Abstract][Full Text] [Related]
2. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma.
Yamauchi N; Watanabe A; Hishinuma M; Ohashi K; Midorikawa Y; Morishita Y; Niki T; Shibahara J; Mori M; Makuuchi M; Hippo Y; Kodama T; Iwanari H; Aburatani H; Fukayama M
Mod Pathol; 2005 Dec; 18(12):1591-8. PubMed ID: 15920546
[TBL] [Abstract][Full Text] [Related]
3. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma.
Capurro M; Wanless IR; Sherman M; Deboer G; Shi W; Miyoshi E; Filmus J
Gastroenterology; 2003 Jul; 125(1):89-97. PubMed ID: 12851874
[TBL] [Abstract][Full Text] [Related]
4. [Selective deposition of agrin in the microvasculature of hepatocellular carcinoma: aspects in pathogenesis and differential diagnosis].
Tátrai P
Magy Onkol; 2008 Dec; 52(4):379-83. PubMed ID: 19068466
[TBL] [Abstract][Full Text] [Related]
5. Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders.
Zhu ZW; Friess H; Wang L; Abou-Shady M; Zimmermann A; Lander AD; Korc M; Kleeff J; Büchler MW
Gut; 2001 Apr; 48(4):558-64. PubMed ID: 11247902
[TBL] [Abstract][Full Text] [Related]
6. Impaired autophagy response in human hepatocellular carcinoma.
Bao L; Chandra PK; Moroz K; Zhang X; Thung SN; Wu T; Dash S
Exp Mol Pathol; 2014 Apr; 96(2):149-54. PubMed ID: 24369267
[TBL] [Abstract][Full Text] [Related]
7. High-affinity monoclonal antibodies to cell surface tumor antigen glypican-3 generated through a combination of peptide immunization and flow cytometry screening.
Phung Y; Gao W; Man YG; Nagata S; Ho M
MAbs; 2012; 4(5):592-9. PubMed ID: 22820551
[TBL] [Abstract][Full Text] [Related]
8. Glypican-3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP-7 signaling.
Midorikawa Y; Ishikawa S; Iwanari H; Imamura T; Sakamoto H; Miyazono K; Kodama T; Makuuchi M; Aburatani H
Int J Cancer; 2003 Feb; 103(4):455-65. PubMed ID: 12478660
[TBL] [Abstract][Full Text] [Related]
9. Nuclear translocation of survivin in hepatocellular carcinoma: a key to cancer cell growth?
Moon WS; Tarnawski AS
Hum Pathol; 2003 Nov; 34(11):1119-26. PubMed ID: 14652813
[TBL] [Abstract][Full Text] [Related]
10. Transformation of primary human hepatocytes in hepatocellular carcinoma.
Montalbano M; Rastellini C; Wang X; Corsello T; Eltorky MA; Vento R; Cicalese L
Int J Oncol; 2016 Mar; 48(3):1205-17. PubMed ID: 26717856
[TBL] [Abstract][Full Text] [Related]
11. Advances in the study of oncofetal antigen glypican-3 expression in HBV-related hepatocellular carcinoma.
Yao M; Wang L; Fang M; Zheng W; Dong Z; Yao D
Biosci Trends; 2016 Nov; 10(5):337-343. PubMed ID: 27795482
[TBL] [Abstract][Full Text] [Related]
12. Biology and function of glypican-3 as a candidate for early cancerous transformation of hepatocytes in hepatocellular carcinoma (Review).
Montalbano M; Georgiadis J; Masterson AL; McGuire JT; Prajapati J; Shirafkan A; Rastellini C; Cicalese L
Oncol Rep; 2017 Mar; 37(3):1291-1300. PubMed ID: 28098909
[TBL] [Abstract][Full Text] [Related]
13. Analysis of intracytoplasmic hyaline bodies in a hepatocellular carcinoma. Demonstration of p62 as major constituent.
Stumptner C; Heid H; Fuchsbichler A; Hauser H; Mischinger HJ; Zatloukal K; Denk H
Am J Pathol; 1999 Jun; 154(6):1701-10. PubMed ID: 10362795
[TBL] [Abstract][Full Text] [Related]
14. Cloning and characterization of a novel 90 kDa 'companion' auto-antigen of p62 overexpressed in cancer.
Soo Hoo L; Zhang JY; Chan EK
Oncogene; 2002 Jul; 21(32):5006-15. PubMed ID: 12118381
[TBL] [Abstract][Full Text] [Related]
15. p62 Expression in primary carcinomas of the digestive system.
Qian HL; Peng XX; Chen SH; Ye HM; Qiu JH
World J Gastroenterol; 2005 Mar; 11(12):1788-92. PubMed ID: 15793865
[TBL] [Abstract][Full Text] [Related]
16. Proliferating cell nuclear antigen expression in normal, regenerative, and neoplastic liver: a fine-needle aspiration cytology and biopsy study.
Ojanguren I; Ariza A; Llatjós M; Castellà E; Mate JL; Navas-Palacios JJ
Hum Pathol; 1993 Aug; 24(8):905-8. PubMed ID: 7690737
[TBL] [Abstract][Full Text] [Related]
17. Immunization with UV-induced apoptotic cells generates monoclonal antibodies against proteins differentially expressed in hepatocellular carcinoma cell lines.
Celikkaya H; Ciraci C; Oztas E; Avci ME; Ozturk M; Yagci T
Hybridoma (Larchmt); 2007 Apr; 26(2):55-61. PubMed ID: 17451351
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of antiglypican-3 therapy as a promising target for amelioration of hepatic tissue damage in hepatocellular carcinoma.
Zaghloul RA; El-Shishtawy MM; El Galil KH; Ebrahim MA; Metwaly AA; Al-Gayyar MM
Eur J Pharmacol; 2015 Jan; 746():353-62. PubMed ID: 25449037
[TBL] [Abstract][Full Text] [Related]
19. Role of Glypican-3 in the growth, migration and invasion of primary hepatocytes isolated from patients with hepatocellular carcinoma.
Montalbano M; Rastellini C; McGuire JT; Prajapati J; Shirafkan A; Vento R; Cicalese L
Cell Oncol (Dordr); 2018 Apr; 41(2):169-184. PubMed ID: 29204978
[TBL] [Abstract][Full Text] [Related]
20. The significance of glypican-3 expression profiling in the tumor cellular origin theoretical system for hepatocellular carcinoma progression.
Xue R; Feng J; Meng Q; Lv F; Zhu Y; Yu H; Zhang S; Song C; Sun L; Yue Z; Feng S; Che R; Xiang Q; Jing X
J Gastroenterol Hepatol; 2017 Aug; 32(8):1503-1511. PubMed ID: 28087980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
